Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

4/1/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AVDL alert in real time by email

DUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 24^th Annual Needham Healthcare Conference on Tuesday, April 8 at 1:30 p.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel's commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:

Austin Murtagh

Precision AQ

[email protected]

(212) 698-8696

Media Contact:

Lesley Stanley

Real Chemistry

[email protected]

(609) 273-3162

Get the next $AVDL alert in real time by email

Date	Price Target	Rating	Analyst
2/11/2025	$12.00	Buy	Deutsche Bank
6/12/2024	$27.00	Buy	Rodman & Renshaw
3/5/2024	$27.00 → $29.00	Outperform	Oppenheimer
3/5/2024	$21.00 → $25.00	Buy	H.C. Wainwright
3/5/2024	$20.00 → $22.00	Buy	Needham
2/6/2024	$21.00	Buy	UBS
11/30/2022	$6.50 → $11.00	Hold → Buy	Jefferies
8/10/2022	$6.00 → $8.00	Buy → Hold	Jefferies

Avadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $AVDL

$AVDL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Gen. Counsel & Corp. Secretary Seurer Jerad G. was granted 14,700 units of Ordinary Shares, increasing direct ownership by 167% to 23,495 units (SEC Form 4)

Chief Financial Officer Mchugh Thomas S was granted 12,600 units of Ordinary Shares, increasing direct ownership by 14% to 100,400 units (SEC Form 4)

Chief Executive Officer Divis Gregory J was granted 52,000 units of Ordinary Shares, increasing direct ownership by 33% to 211,100 units (SEC Form 4)

$AVDL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Deutsche Bank initiated coverage on Avadel Pharmaceuticals with a new price target

Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

Oppenheimer reiterated coverage on Avadel Pharmaceuticals with a new price target

$AVDL Press Releases

Fastest customizable press release news feed in the world

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction

$AVDL Leadership Updates

Live Leadership Updates

Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales

Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement

Avadel Pharmaceuticals to Join Russell 3000® Index

$AVDL Financials

Live finance-specific insights

Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

$AVDL SEC Filings

SEC Form 10-Q filed by Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Avadel Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$AVDL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

$AVDL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Palczuk Linda bought $39,640 worth of Ordinary Shares (5,000 units at $7.93), increasing direct ownership by 8% to 67,900 units (SEC Form 4)

Director Thornton Peter J. bought $80,450 worth of Ordinary Shares (10,000 units at $8.04), increasing direct ownership by 11% to 104,055 units (SEC Form 4)

Director Ende Eric J bought $235,218 worth of Ordinary Shares (30,000 units at $7.84), increasing direct ownership by 17% to 208,900 units (SEC Form 4)

Recent Analyst Ratings for
$AVDL

$AVDL
Insider Trading

$AVDL
Analyst Ratings

$AVDL
Press Releases

$AVDL
Leadership Updates

$AVDL
Financials

$AVDL
SEC Filings

$AVDL
Large Ownership Changes

$AVDL
Insider Purchases